Key result
CPU 86017 exerted dose-dependent antiarrhythmic effects in animal models, with an ED50 of 2.10 μM against ventricular fibrillation, and was 10 times more potent than intravenous lidocaine.
Why the study?
Does CPU 86017 suppress arrhythmias induced by ischemia/reperfusion, ouabain, and aconitine in animal models?
Does CPU 86017 suppress arrhythmias induced by ischemia/reperfusion, ouabain, and aconitine in animal models?
CPU 86017 demonstrates potent, dose-dependent antiarrhythmic and antifibrillatory effects across multiple preclinical models of arrhythmia.
Hypothesis-generating for CPU 86017 in arrhythmia suppression; human trials required before any clinical consideration.
Protection by CPU 86017 against reperfusion-induced arrhythmias was studied in Langendorff perfused hearts and anesthetized rats. Inhibition of arrhythmias induced by ouabain and aconitine was observed, and the influence of CPU 86017 on ventricular fibrillation threshold (VFT) was determined. CPU 86017 exerted a dose-dependent antiarrhythmic effect in animal models. In Langendorff's perfused hearts, CPU 86017 significantly reduced the incidence and duration of ventricular fibrillation and ventricular tachycardia, as well as arrhythmic scores in a dose-dependent manner. The approximate ED50 of CPU 86017 against ventricular fibrillation was 2.10 μM. The antiarrhythmic effect of CPU 86017 against arrhythmia persisted for more than 6 h. In anaesthetized rats, CPU 86017 provided potent antiarrhythmic and antifibrillatory effects by po or iv routes. CPU 86017 was similar in potency to propafenone by the po route, and 10 times more potent than lidocaine by the iv route. CPU 86017 significantly attenuated the exaggerated arrhythmia and ventricular fibrillation in hypertrophic hearts induced by 1-thyroxine. Against ouabain-induced arrhythmias CPU 86017 exerted a dose-dependent inhibitory effect, which was 6.5-fold more potent than berberine. CPU 86017 significantly reduced ventricular fibrillation incidence and prevented the further deterioration of ventricular arrhythmias induced by aconitine. In conclusion, CPU 86017 is a potent antiarrhythmic agent with multiple mechanisms of action. Drug Dev. Res. 39:184–190.
No takes yet. Share an insight, caveat, or question.
Dai et al. (1996) studied Induced arrhythmias. CPU 86017 vs. Propafenone, lidocaine, and berberine was evaluated on Incidence and duration of ventricular fibrillation and ventricular tachycardia. CPU 86017 exerted dose-dependent antiarrhythmic effects in animal models, with an ED50 of 2.10 μM against ventricular fibrillation, and was 10 times more potent than intravenous lidocaine.
Synapse has enriched 5 related papers. Consider them for comparative context: